• Home
  • »
  • Newsroom
  • »
  • Alexion to Highlight Robust Rare Disease Pipeline at Investor Day

Alexion to Highlight Robust Rare Disease Pipeline at Investor Day

Thursday, November 19, 2015 10:00 am EST



Public Company Information:


CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced that the Company will host an Investor Day on Thursday, December 10, 2015 from 12:00 p.m. to 5:00 p.m. Eastern Standard Time in New York City.

Alexion’s leadership team will highlight the continued advancement of the Company’s highly innovative early and late-stage pipeline which is focused on serving patients with devastating and rare diseases. The company will also provide updates on key aspects of its long-term growth strategy for its complement and metabolic franchises.

Webcast/Conference Call Information

The presentation will be broadcast via a live webcast which can be accessed on the Investor page of Alexion’s website at: http://ir.alexionpharm.com. A replay of the webcast will be archived on the website following the presentation. To participate in this conference call, dial 866-546-3377 (USA) or 719-234-7872 (International), passcode 737 644 3057 shortly before 12:00 p.m. ET.

About Alexion

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq™ (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas. This press release and further information about Alexion can be found at: www.alexion.com.



Alexion Pharmaceuticals Inc.
Stephanie Fagan, 203-271-8223
Senior Vice President, Corporate Communications
Kim Diamond, 203-439-9600
Executive Director, Corporate Communications
Elena Ridloff, CFA, 203-699-7722
Executive Director, Investor Relations